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The increasing incidence of fractures related
to osteoporosis in both females and males has
led to efforts to increase bone mass, especially
in young children and adolescents (1). It is
recognized, even in developed countries such
as the United States, that daily intakes of cal-
cium among children are below recom-
mended levels (2,3). One approach to
increase bone mass has been with vitamin and
mineral supplementation; another has been
fortiﬁcation of foodstuffs such as cereals.
In addition to the potential to increase
bone mass, calcium supplementation offers
other advantages at various stages of life. For
example, calcium supplementation reduces
the incidence of pregnancy-induced hyper-
tension and preeclampsia (4). In addition,
Koo et al. (5) showed that supplementation
with 2 g calcium per day increased fetal bone
density in subjects whose calcium intake was
normally < 600 mg per day. Of relevance to
our study is the recognition that lead absorp-
tion by the gastrointestinal tract is increased
in calcium-deﬁcient diets (6). Absorption of
lead by the gastrointestinal tract is inversely
related to the amount of calcium present
(6,7). Furthermore, calcium supplements
had a protective effect by signiﬁcantly reduc-
ing blood lead levels in pregnant women
whose diets were deﬁcient in calcium (8,9).
The increased mobilization of skeletal lead
during pregnancy and lactation was attrib-
uted to low calcium intake (10).
As people have been encouraged to take
calcium supplements, several investigators
have drawn attention to their potential lead
toxicity (11–15). Furthermore, the lead
concentrations in calcium supplements were
the subject of California legal action,
Proposition 65 (16).
Any lead contained in calcium supple-
ments will be introduced in conjunction
with the calcium. Lead binds tightly to the
same transport proteins used by calcium, but
the binding affinity of lead is at least twice
that of calcium (17). Because the same trans-
port mechanism is operative for absorption
of lead and calcium from the gastrointestinal
tract, there is resulting competitive interac-
tion between lead and calcium (18). 
The agreement reached between the
California Attorney General and supplement
manufacturers for Proposition 65 was an
acceptable daily intake of < 1.5 µg Pb/g Ca
for adults (15,16). Even at these levels, how-
ever, supplements potentially contribute a
signiﬁcant proportion of the daily intake of
lead that is now < 5 µg/day in the United
States (19).
We were concerned about the scientific
validity of the California judgment in light of
earlier investigations from tracer studies in
both animals and humans demonstrating lim-
ited uptake of lead from the gastrointestinal
tract in the presence of calcium (± phospho-
rus; Figure 1) (20–24). These experiments,
however, were undertaken at times of con-
siderably higher intakes of lead with small
numbers of subjects and mostly over limited
time periods. The publicity arising from the
California legal action was of concern
because we had just begun a clinical trial in
which subjects were given calcium supple-
ments to verify the hypothesis that calcium
supplementation minimizes the mobilization
of skeletal lead during pregnancy and lacta-
tion. To satisfy ourselves and participants in
our trial of the potential safety of calcium
supplements and the minimal contribution
to blood lead, we undertook a case–control
study in which adults consumed calcium
supplements containing lead whose isotopic
composition was different from that in their
current blood.
The question we asked was, does the
amount of lead in calcium supplements
increase blood lead concentration or change
the isotopic composition of lead in blood at
the recommended daily intake levels of
calcium?
Methods
Rationale. We demonstrated previously that
the lead isotopic composition of multigener-
ational Australians was different from that
of subjects from most other countries (10).
We used this concept, first suggested by
Manton (25), in our longitudinal study of
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We conducted a case–control study to determine the contribution of lead to blood from con-
sumption of calcium supplements approximating the recommended daily intakes over a 6-month
period. Subjects were males and females ages 21 to 47 years (geometric mean 32 years) with a
geometric mean blood lead concentration of 2.5 µg/dL. They were subdivided into three groups.
One treatment group (n = 8) was administered a complex calcium supplement (carbonate/phos-
phate/citrate) and the other treatment group (n = 7) calcium carbonate. The control group (n = 6)
received no supplement. The lead isotopic compositions of the supplements were completely dif-
ferent from those of the blood of the subjects, allowing us easily to estimate contribution from
the supplements. The daily lead dose from the supplements at 100% compliance was about 3 µg
Pb. Three blood samples were taken at 2-month intervals before treatment to provide background
values, and three were taken during treatment. Subjects in the treatment group were thus their
own controls. Lead isotopic compositions for the complex supplement showed minimal change
during treatment compared with pretreatment. Lead isotopic compositions in blood for the cal-
cium carbonate supplement showed increases of up to 0.5% in the 206Pb/204Pb ratio, and for all
isotope ratios there was a statistically signiﬁcant difference between baseline and treatment (p <
0.005). The change from baseline to treatment for the calcium carbonate supplement differed
from that for both the control group and the group administered the complex supplement. Blood
lead concentrations, however, showed minimal changes. Variations in blood lead levels over time
did not differ signiﬁcantly between groups. Our results are consistent with earlier investigations
using radioactive and stable lead tracers, which showed minimal gastrointestinal absorption of
lead in the presence of calcium (± phosphorus) in adults. Even though there is no discernible
increase in blood lead concentration during treatment, there are significant changes in the iso-
topic composition of lead in blood arising from the calcium carbonate supplement, indicating a
limited input of lead from diet into the blood. Because calcium carbonate is overwhelmingly the
most popular calcium supplement, the changes we have observed merit further investigation. In
addition, this type of study, combined with a duplicate diet, needs to be repeated for children,
whose fractional absorption of lead is considerably higher than that of adults. Key words: blood
lead, calcium supplements, isotopes, lead. Environ Health Perspect 109:283–288 (2001). [Online
2 March 2001]
http://ehpnet1.niehs.nih.gov/docs/2001/109p283-288gulson/abstract.htmlmobilization of lead from the maternal
skeleton during pregnancy and lactation.
Commercially available Australian calcium
supplements, which are typically made from
overseas components, were administered to
the subjects.
Subjects and dosing. Subjects, 8 males
and 13 females, ranged in age from 21 to 47
years with a geometric mean of 32 years. We
attempted to assign subjects randomly to
one of three groups, two treatment and one
control group, but two subjects expressed a
desire to be in the control group. This does
not, however, confound our results, because
the treatment subjects formed their own
controls by having three baseline measure-
ments. The others were randomly assigned
to the treatment groups. Ethics clearance was
obtained from Macquarie University.
Sampling. A trained phlebotomist
obtained 2–3 mL of venous blood from each
subject. Three samples were collected at
quarterly intervals to establish a background
value before treatment. During treatment,
samples were collected bimonthly for 6
months of calcium supplementation. Thus,
each subject in the treatment group acted as
his or her own control. Because of changes
observed by the group given the calcium car-
bonate supplement, an additional blood
sample for this group was taken 2 months
after the treatment ended to see if there was
a trend toward the baseline values.
Treatment. We originally intended to
use a popular calcium carbonate product,
but it was not possible to obtain the required
quantity of a single manufacturing batch
from the supplier. However, for the two
treatment supplements, sufficient product
was obtained from the one batch of produc-
tion to minimize variability in the source of
calcium and hence lead. The possibility of
supplying the control group with a placebo
was investigated but discarded because of
production difﬁculties for such a small batch.
The product details are listed in Table 1. The
complex supplement was to be taken 3 times
daily, with meals and at bedtime, because the
fasting state is a time when most parathyroid
hormone-mediated bone resorption occurs
(26). The calcium carbonate was taken twice
daily after meals.
Two subjects experienced nauseous reac-
tions which they possibly attributed to the
calcium supplements. One subject, given the
complex product, had just conceived and
was therefore moved to the control group.
The other experienced nausea taking the cal-
cium carbonate product; the subject was
switched to the alternative supplement and
thereafter showed no adverse effects.
In this pilot investigation, we did not
attempt to undertake a dietary study apart
from a questionnaire. However, our previous
and ongoing pregnancy research showed that
the daily calcium intake of migrant and
Australian subjects is low (about 500 mg
Ca/day) compared with the recommended
levels for subjects participating in U.S. stud-
ies on pregnancy and lactation (27–32). In
these studies, based on diaries and recall, cal-
cium intake was estimated at 1,200–1,800
mg Ca/day, compared with 300–800 mg
Ca/day for our subjects (10).
Questionnaire. On one occasion we gave
the participants a questionnaire that placed a
special emphasis on the intake of potentially
calcium-bearing foods.
Analyses. All sample preparation was per-
formed in purpose-built low-contamination
laboratories (clean rooms) incorporating fea-
tures such as ﬁltered air intake and laminar
flow hoods. To minimize sample hetero-
geneity, the total blood sample was predi-
gested in ultrapure concentrated nitric acid
and an aliquot of < 1g removed to a clean
Teflon vessel. A 202Pb spike solution of
known isotopic composition and lead con-
centration (~ 10 ng/g) was added to the
aliquot to obtain the concentration of lead
and isotopic composition of the unknown
sample in the one analysis (this is known as
the isotope dilution method). (202Pb is not
naturally occurring and is produced in
cyclotrons as a by-product of preparation of
thallium used in treatment of thyroid abnor-
malities; it has a half-life of about 3 ×  105
years.) We analyzed the calcium supple-
ments for their lead isotopic composition by
first spiking with the 202Pb spike and then
dissolving/digesting in ultra-pure nitric acid.
An aliquot was removed to a clean Teflon
vessel and its pH was adjusted using clean
ammonia. We separated lead from the cal-
cium by passing the solution through a
chelex ﬁlter. We further separated lead from
other interfering ions using anion exchange
chromatography in a bromide medium. 
For isotope ratio measurement, we
loaded fractions of the puriﬁed lead samples
onto a rhenium ﬁlament using the silica gel
technique (a mix of dilute phosphoric acid
and puriﬁed silica gel) and analyzed them for
lead isotope composition (and lead concen-
trations by isotope dilution) on a thermal
ionization mass spectrometer (VG-ISO-
MASS 54E; VG, Winsford, Cheshire, UK)
run in fully automatic mode. Isotopic ratios
were measured as 208Pb/206Pb, 207Pb/206Pb,
and 206Pb/204Pb. Precision estimates on the
isotopic ratios have been deﬁned by a repeti-
tion of the digestion/lead separation/mass
spectrometry stages of the same samples of
blood, urine, and water. The precisions we
allocate our data are ± 0.2% (2 σ ) on the
206Pb/204Pb ratio, and ± 0.1% on the
208Pb/206Pb and 207Pb/206Pb ratios. Data are
normalized to the accepted values of the
National Institute of Standards and
Technology (NIST) SRM 981 by applying a
correction factor of +0.08% atomic mass
units to allow comparisons between labora-
tories. We obtained a measurement of the
environmental lead acquired by the sample
throughout the entire preparation analysis
procedure in the form of a lead blank mea-
surement. The amount of contamination
detected in blanks was generally around 200
pg for blood and from 300 to 900 pg for the
calcium supplements. Because the blanks
contributed negligibly to the lead in the
sample, no blank corrections to the data
were performed.
Data treatment. We analyzed the three
isotopic ratios (208Pb/206Pb, 207Pb/206Pb,
and 206Pb/204Pb) and lead concentrations
using a 2 (baseline and treatment) × 3 (days
1, 2, and 3 of baseline and treatment) ×  3
(the control, calcium carbonate, and calcium
citrate groups) factorial design. The ﬁrst two
factors were within-subject factors. 
Results 
Results are summarized in Table 2, and a
comparison of means of the 206Pb/204Pb
ratio and blood lead concentrations for each
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Figure 1. Decreases in lead absorption in the
presence of calcium and phosphorus [data from
Blake and Mann (20)]. 
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Table 1. Product information.
Complex product 
Calcium Calcium Calcium  Calcium  carbonate
Composition citrate phosphate amino acid (chewable)
Weight Ca compound (mg) 300 325 200 1,250
Equivalent Ca (mg) 64 126 40 500
Daily total Ca (mg)  920 1,000
Daily dosage 3 times after meals; 1 on retiring 2 times after meals
206Pb/204Pb 20.14 19.70
Pb (µg/kg) 293 700
Daily Pb intake (µg/day) 2.8 3.2group is shown in Figures 2 and 3.
Compliance for the 3 months of the treat-
ment period ranged from 0 to 100% for
each month. It was expected that changes in
pretreatment blood samples may have been
larger because sampling covered the
Christmas holidays, a time of increased
dietary intake and consumption of unusual
foods. We sampled approximately 1 month
after Christmas to minimize potential effects
of abnormal dietary intakes, because the
mean life of lead in blood of adults is
approximately 20 days (33, 34).
Blood lead concentrations. We observed
a slight downward trend over time in blood
lead concentrations (Table 2, Figure 3),
which was reﬂected in a main effect of treat-
ment (F(1,14) = 5.94, p = 0.029) and also in a
day main effect (F(2,28) = 4.12, p = 0.027).
However, the change over days did not differ
for baseline and treatment (for the day-by-
treatment interaction, F(2,28) = 0.34, p =
0.717), and, as will be seen below, there was
no suggestion of a group-by-treatment inter-
action.
Blood lead isotopic ratios. Apart from
the anomalies described below, there were
minimal changes in isotopic ratios in the
control subjects and those given the complex
supplement (Figure 2). In contrast, there
were detectable increases in 206Pb/204Pb
ratio during administration of the calcium
carbonate toward the values in the supple-
ment (Figure 2; p = 0.002). Significant
changes in the calcium carbonate group
from baseline to treatment also occurred for
208Pb/206Pb and 207Pb/206Pb (p < 0.0005
and p = 0.001, respectively). The blood
sample taken 2 months after treatment
ended showed a decrease toward the base-
line values for 206Pb/204Pb in some cases,
indicating that the increases toward the sup-
plement noted above were a valid effect.
There was also a small decrease in blood
lead concentration after cessation of treat-
ment (Figure 3).
Anomalies in subjects. As is becoming
increasingly evident in human studies, indi-
vidual susceptibility to toxins or treatments
plays a major role in determining impacts on
health, as do changes in the environment of
subjects. In our study, such problems arose
for several subjects. For example, male sub-
ject 1305 undertook renovations using
unsafe methods to an external garage with
lead paint just before the start of treatment.
Both he and  his wife (subject 1306) experi-
enced a sharp decrease in 206Pb/204Pb ratio
in blood Pb and an increase in blood lead
(PbB) concentration (Table 2). The low
206Pb/204Pb ratio in their blood is consistent
with that of much of the lead in paint used
in the past on Australian houses (35). Such
changes, especially in isotopic compositions,
associated with renovation of leaded paint
were documented earlier by Manton (36).
Despite the changes associated with renova-
tion, the increases in isotopic composition
that occur while taking calcium carbonate
are consistent with the increases noted
above.
One control subject (1302) was a regular
firearms shooter, and large changes in PbB
and isotopic composition are consistent with
lead exposure from this activity. His data
were omitted from the discussion and will be
documented separately. 
A husband and wife control pair (1322,
1323) exhibited small changes in PbB and
isotopic composition after an 11-day visit
to the United States (Table 2). High
206Pb/204Pb ratios are characteristic of U.S.
subjects and many environmental and
dietary media (39). 
Statistical analyses. We omitted the data
for the anomalous subjects 1302, 1305, and
1306 from the statistical analyses.
Significant interactions between group and
treatment were found for all blood lead iso-
topic ratios (p-values for F-ratios with 2 and
14 degrees of freedom ranged from 0.01 for
208Pb/206Pb through 0.023 for 207Pb/206Pb
to 0.027 for 206Pb/204Pb). The group-by-
treatment interaction was not signiﬁcant for
lead concentrations (p = 0.402). We fol-
lowed up the signiﬁcant interactions by test-
ing interaction contrasts to answer the
question, does the change between baseline
and treatment differ for different pairs of
groups? Two contrasts compared the cal-
cium carbonate product and the complex
calcium citrate product to the controls. The
third contrast compared the complex cal-
cium citrate product to the calcium carbon-
ate product. The results are listed in Table 3.
Using an adjusted α level of 0.0167 (0.05/3)
to allow for the three contrasts, there was a
significant difference in the change from
baseline and treatment for the calcium car-
bonate product and the control group for
the 208Pb/206Pb ratio (p = 0.008) and close
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Table 2. Changes in lead isotopic composition and blood lead for subjects.
Pretreatment Changes during treatment Posttreatment sample
PbB PbB PbB Compliancea
Identiﬁer Age (years) Sex (µg/dL) 206Pb/204Pb (µg/dL) 206Pb/204Pb (µg/dL) 206Pb/204Pb (%)
Calcium citrate/phosphate/chelate
1303 31 M 3.5 17.19 3.2–2.9 17.21–17.25 — — 70–100
1304 38 M 2.1 17.22 2.1–1.4 17.22–17.32 — — 87–94
1309 34 M 1.4 17.21 1.3–1.4 17.19–17.34 — — 73–78
1311 47 F 5.8 16.66 5.2–5.7 16.68–16.70 — — 76–90
1313 21 F 2.5 17.32 2.3–2.6 17.24–17.33 — — 0–50
1314 30 F 3.1 17.49 3.1–3.8 17.42–17.52 — — 21–59
1315 44 F 2.2 17.22 1.5–1.4 17.24–17.28 — — 86–92
1321 27 F 1.8 17.45 1.5–1.5 17.36–17.54 — — 29–40
Calcium carbonate
1305b 39 M 4.5–7.8 16.76–16.39 6.9–4.5 16.48–16.84 4.1 16.88 94–100
1306b 36 F 2.2–3.5 17.36–16.93 2.2–1.9 17.25–17.46 1.9 17.53 74–90
1308 32 F 3.5–4.3 16.84 5.1–3.3 17.31–17.42 2.6 17.34 70–89
1312 25 F 2.1 17.39 2.3–2.1 17.49–17.64 1.6 17.51 84–96
1316 27 F 1.5 17.52 1.4–1.5 17.63–17.70 1.3 17.58 70–86
1319 33 F 2.1 17.35 2.0–2.6 17.32–17.47 2.1 17.38 17–62
1320 30 F 1.2 17.28 1.2–1.4 17.36–17.38 1.0 17.33 29–40
Controls
1302b 38 M 3.2–6.7 17.39–17.10 3.8–6.0 17.58–17.21 —— —
1307 32 M 2.3 17.26 2.9–2.1 17.23–17.24 —— —
1317 23 F 1.8 17.37 1.5 17.37–17.38 —— —
1318 39 M 1.7 17.20 1.3–1.5 17.21–17.26 —— —
1322b 25 F 2.4 17.24 2.3–1.8 17.54–17.35 —— —
1323b 31 M 2.4 17.36 2.6–2.2 17.43–17.35 —— —
aCompliance each month over the 3 months of treatment. bPossible reasons for the larger variability in isotopic composition and lead concentration are given in the text.to signiﬁcant differences for the 207Pb/206Pb
and 206Pb/204Pb ratios (p = 0.028 and 0.030,
respectively). In contrast, there was no sug-
gestion of signiﬁcant differences between the
control and calcium citrate groups (p > 0.5
for each measure). The third contrast
showed that the change for calcium carbon-
ate product differed significantly from that
for the calcium citrate product for each of
the three measures (p < 0.010 in each case).
The overall result was that the change from
baseline to treatment for the calcium carbon-
ate group differed from that for both the
control and calcium citrate groups.
Discussion
Contribution to blood of lead from supple-
ments. Over the 6-month dosing period, the
potential impact on blood lead from the two
calcium supplements tested in this pilot
study was not detectable in the case of the
complex product and only a small contribu-
tion was detected in the case of the calcium
carbonate product. For the calcium carbon-
ate product, there was little or no change in
blood lead concentration but detectable
changes in isotopic composition toward the
206Pb/204Pb value of 19.7 in the supplement.
Changes in isotopic composition toward the
contributing source but not in blood lead
concentration were observed in some other
studies on newborn infants (37) and percu-
taneous absorption of lead (38). This may
indicate that the pharmacokinetics of lead in
blood need to be reevaluated, as also indi-
cated by the long half-lives of lead in blood
of up to 38 months observed in several
young infants unnaturally exposed to lead
from home renovations (39). With the
changes in isotopic composition in blood
compared with those in the pretreatment
phase of calcium carbonate relative to the
values in the product, the maximum contri-
bution to blood lead is < 0.5%. 
Indirect evidence supporting the protec-
tive effect of calcium (calcium carbonate ±
phosphorous) comes from our longitudinal
investigation on mobilization of lead from
the maternal skeleton during pregnancy and
lactation. In four pregnant subjects who
were given calcium supplements (calcium
carbonate or calcium citrate from the present
study), minimal changes in blood lead con-
centration and isotopic composition were
observed during pregnancy and lactation
(40).
Effect of type of supplement. Given the
competition of calcium and lead, an addi-
tional factor contributing to the uptake of
lead from the gastrointestinal tract is the rela-
tive absorption of calcium from different
compounds. The absorption of calcium from
calcium carbonate and calcium citrate alone
is approximately 30% (41). The absorption
may be higher for the complex product of
calcium citrate/phosphate/chelate, but to our
knowledge this has not been rigorously tested
using isotopic tracing methods.
Effect of state of the gut. Another impor-
tant factor affecting gastrointestinal absorp-
tion is the relative condition of the
gut—that is, whether it is in a fasted or non-
fasted state. Tracer studies have demon-
strated that in the absence of additional
calcium, gastrointestinal absorption of lead
was greater when lead was ingested by fast-
ing subjects given soluble lead compounds in
distilled water than when lead was ingested
in the presence of food. Lead absorption in
nonfasted subjects on either a normal diet or
a controlled diet, in which nutritional con-
tent was known, ranged from approximately
3% to 10%, whereas lead absorption in
fasted subjects who received soluble lead in
distilled water (with no additional calcium)
ranged from approximately 30% to 76%
(20–24,33,34). The absence of calcium and
other minerals in the gastrointestinal tract at
the time of lead ingestion is a major reason
for increased lead absorption in fasting sub-
jects compared with nonfasting subjects
(20–24,33,34), although when calcium and
other minerals are present, differences seen
between fasting and nonfasting subjects
essentially disappear (22,23,32).
Effect of minerals on absorption. The
presence of other minerals than calcium is an
important factor in lead absorption from the
gastrointestinal tract. For example, lead
absorption decreases as calcium (± phospho-
rous) concentrations increase (Figure 1)
(20,22). Lead absorption in fasting subjects
given lead chloride in drinking water was
reduced by 83% and 97% when the lead was
given with calcium and phosphorous at
intakes of 200 mg Ca + 140 mg P and 700
mg Ca + 500 mg P, respectively (22).
Reductions in lead absorption and retention
were noted with both calcium alone (as cal-
cium carbonate) and phosphorous alone (as
sodium phosphate), but calcium was much
more effective than phosphorous (20,22).
The larger decreases in absorption for calcium
phosphate compared with calcium carbonate
observed by Blake and Mann (20) (Figure 1)
may explain the absence of any effect of the
complex product used in our study.
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Figure 2. Variation in mean 206Pb/204Pb ratio for the different groups over time.
The 206Pb/204Pb ratio was 19.7 in the calcium carbonate supplement and 20.14
in the complex supplement, so any contribution from these supplements to
blood lead should be easily discernible. Beginning of the administration of the
supplement is denoted by “Start” and termination by “End.” An additional sam-
ple posttreatment was taken for the calcium carbonate supplement to verify its
potential effect on the blood lead of subjects. The data for the “anomalous”
subjects 1302, 1305, and 1306 are not included in the analysis. The error bars
indicate the maximum SE measured at each stage.
Figure 3. Variation in PbB (µg/dL) for the different groups over time. The daily
intake of lead from the supplements is about 3 µg Pb. Beginning of the adminis-
tration of the supplement is denoted by “Start” and termination by “End.”
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infants and young children is also inﬂuenced
by dietary calcium intake. For example,
Ziegler et al. (42) observed an inverse rela-
tionship between dietary calcium and reten-
tion and lead absorption in young infants in
metabolic balance studies. Dietary calcium
and phosphorus were important predictors
of blood lead concentrations in children
12–47 months of age from a low-income
population in central Washington, D.C.
(43). Likewise, Sorrell et al. (44) and
Johnson and Tenuta (45) observed inverse
correlations between lead and calcium
intake, vitamin D, and milk-based foods.
Reductions in lead absorption were also
noted in subjects ingesting different foods,
depending on the calcium and mineral con-
tent of the ingested meal (24).
Animal studies. Studies using fasted and
nonfasted laboratory animals, including rats,
mice, and monkeys, have produced results
similar to those in humans (46–49). For
example, Mahaffey-Six and Goyer (46) and
Mahaffey et al. (47) reported that rats ingest-
ing a low-calcium diet had blood lead con-
centrations approximately 4 times higher
than rats consuming a normal calcium diet.
Later studies showed that gastrointestinal
absorption of lead decreases in the presence
of a number of minerals (50–52). Increasing
calcium concentrations were found to
decrease lead retention exponentially as cal-
cium concentrations increased (49). As in
the human studies, administration of phos-
phorous without calcium did not produce
reductions in lead retention as great as that
for calcium alone or for calcium with phos-
phorous (50).
Effect of dosing regime. An additional
protective effect associated with the complex
product may come from its dosing regime.
This supplement was to be taken 4 times
daily including at bedtime because the fast-
ing state is a time when most parathyroid
hormone-mediated bone resorption occurs
(26). The calcium carbonate was taken twice
daily after meals. Heaney (26) recommended
a daily dosing regime of 4 times because,
although the amount of a mineral absorbed
continues to rise with the intake, the per-
centage absorbed falls.
Matrix effects. The minimal effects
observed in our pilot study may also be
caused partly by matrix effects of the prod-
ucts. In studies of fasted human subjects,
lead was administered as dissolved salts or
suspended in solution. Using absorption val-
ues for lead in a solution as representative of
lead absorption from a complex matrix may
produce an overestimate of lead absorption.
Before absorption, lead must dissociate from
the compound to which it is bound. This
may explain the difference between the com-
plex calcium citrate and the calcium carbon-
ate; the latter was in a chewable form and
more easily absorbed.
Effect of duration of investigations. The
length of time over which a study is under-
taken may also be an important factor in
absorption of lead from the gastrointestinal
tract. Unlike the investigations by Rabinowitz
et al. (23,33), the other studies involving
radioactive tracers were only of short dura-
tion—less than 7 days. Our treatment period
was 6 months, but we were able to detect
increases in isotopic composition for calcium
carbonate supplement. Because calcium car-
bonate is the most popular supplement (53),
the potential uptake of lead from this product
should be veriﬁed in a more comprehensive
investigation, especially of young children.
Daily intake of lead from supplements.
The amounts ingested from the two supple-
ments of approximately 3 µg Pb/day are
more than half the current daily lead intake
of less than 5 µg Pb/day for the United
States (19)—despite the temporal decrease
in the amount of lead in supplements illus-
trated by Scelfo and Flegal (15). Lanphear
and colleagues recently demonstrated that
lead shows detrimental effects in children at
blood concentrations as low as 2.5 µg/dL
(54). Hence, any source contributing 50%
or more to lead exposure—especially in
young children, with lead absorption greater
than that of adults—requires investigation
and monitoring.
In conclusion, despite the fact that lead
exposure from the calcium supplements
tested in this study was approximately half
the daily intake of lead, the contribution to
blood lead concentration was minimal.
However, the same may not apply to cal-
cium-fortified foods. Furthermore, even
though there is no discernible increase in
blood lead concentration, there are signifi-
cant changes in the isotopic composition of
lead in blood arising from the calcium car-
bonate supplement, which indicate a limited
input of lead from diet into the blood.
Because calcium carbonate is the over-
whelmingly most popular calcium supple-
ment, the changes we have observed merit
further investigation. The small contribu-
tions of lead from calcium supplements,
however, should not discourage people from
their usage given other significant benefits
deriving from calcium. 
REFERENCES AND NOTES
1. NIH. Osteoporosis and Fractures in Men. NIH Guide, Vol
25, No 39. PA-97-009. Bethesda, MD:National Institutes
of Health, 1996. 
2. NIH Consensus Development Panel on Optimal Calcium
Uptake. JAMA 272:1942–1948 (1994). 
3. Standing Committee on the Scientific Evaluation of
Dietary Reference Intakes. Food and Nutrition Board,
Institute of Medicine. Dietary Reference Intakes for
Calcium, Phosphorus, Magnesium, Vitamin D, and
Fluoride. Washington, DC:National Academic Press, 1997.
4. Bucher HC, Guyatt GH, Cook RJ, Hatala R, Cook DJ, Lang
JD, Hunt D. Effect of calcium supplementation on preg-
nancy-induced hypertension and preeclampsia. JAMA
275:1113–1117 (1996). 
5. Koo WW, Walters JC, Esterlitz J, Levine RJ, Bush AJ,
Sibai B. Maternal calcium supplementation and fetal
bone mineralization. Obstet Gynecol 94:577–582 (1999).
6. Mahaffey KR. Factors modifying susceptibility to lead
toxicity. In: Dietary and Environmental Lead: Human
Health Effects (Mahaffey KR, ed). Amsterdam:Elsevier,
1985;373–419.
7. Goyer RA. Nutrition and metal toxicity. Am J Clin Nutr
61(Suppl):646S–650S (1995). 
8. Farias P, Borja-Aburto VH, Rios C, Hertz-Picciotto I, Rojas-
Lopez M, Chavez-Ayala R. Blood lead levels in pregnant
women of high and low socioeconomic status in Mexico
City. Environ Health Perspect 104:1070–1074 (1996).
9. Hernandez-Avila M, Gonzalez-Cossio T, Palazuelos E,
Romieu I, Aro A, Fishbein E, Peterson KE, Hu H. Dietary
and environmental determinants of blood and bone lead
levels in lactating postpartum women living in Mexico
City. Environ Health Perspect 104:1076–1082 (1996). 
10. Gulson BL, Mahaffey KR, Jameson CW, Mizon KJ,
Korsch MJ, Cameron MA, Eisman JA. Mobilization of
lead from the skeleton during the post-natal period is
larger than during pregnancy. J Lab Clin Med
131:324–329 (1998).
11. Capar SG, Gould JH. Lead, ﬂuorine and other elements in
bonemeal supplements. J Assoc Off Anal Chem
62:1054–1061 (1979).
12. Boulos BM, Smolinski A. Alert to users of calcium sup-
plements as hypertensive agents due to trace metal con-
taminants. Am J Hypertens 1:137S–142S (1988).
13. Bourgoin BP, Evans DR, Cornett JR, Lingard SM,
Quattrone AJ. Lead content in 70 brands of dietary cal-
cium supplements. Am J Public Health 83:1155–1160
(1993).
14. Rogan WJ, Ragan NB, Damokosh AL, Davolie C, Shaffer
TR, Jones RL, Wilkens S, Heenehan MC, Ware JW,
Henretig F. Recall of a lead-contaminated vitamin and
mineral supplement in a clinical trial. Pharmacoepidemiol
Drug Saf 8:343–350 (1999).
15. Scelfo GM, Flegal AR. Lead in calcium supplements.
Environ Health Perspect 108:309–313 (2000).
16. California Attorney General’s Office. Superior Court
Articles • Lead in calcium supplements
Environmental Health Perspectives • VOLUME 109 | NUMBER 3 | March 2001 287
Table 3. Interaction contrasts.
Analysis Coefﬁcient SE t-Value p-Value
208Pb/206Pb
Calcium carbonate vs. control –0.01692 0.00548 –3.0898 0.00799
Calcium citrate vs. control –0.00011 0.00465 –0.02456 0.98075
Calcium citrate vs. calcium carbonate –0.01681 0.00500 3.3618 0.00465
207Pb/206Pb
Calcium carbonate vs. control –0.01015 0.00414 –2.4480 0.02815
Calcium citrate vs. control –0.00155 0.00352 0.4405 0.66631
Calcium citrate vs. calcium carbonate 0.01169 0.00378 3.0918 0.00796
206Pb/204Pb
Calcium carbonate vs. control 0.22127 0.09147 2.4190 0.02977
Calcium citrate vs. control –0.02776 0.07774 –0.35711 0.72633
Calcium citrate vs. calcium carbonate –0.24903 0.08350 –2.9823 0.00989Settlement No. 984503. San Francisco, CA, 15 May
1997. Available: http://www.prestongates.com/news-
room/dietary_supplement/consent_judgment.htm
[cited 5 February 2001].
17. Heaney RP. Unpublished data. 
18. Mushak P. Gastro-intestinal absorption of lead in children
and adults: overview of biological and biophysico-chemi-
cal aspects. Chem Speciat Bioavaiabl 3:87–104 (1991).
19. Bolger M. Personal communication.
20. Blake KCH, Mann M. Effect of calcium and phosphorus
on the gastrointestinal absorption of 203Pb in man.
Environ Res 30:188–194 (1983).
21. Blake KCH, Barbezat GO, Mann M. Effect of dietary con-
stituents on the gastrointestinal absorption of 203Pb in
man. Environ Res 30:182–187 (1983).
22. Heard MJ, Chamberlain AC. Effect of minerals and food
on uptake of lead from the gastrointestinal tract of
humans. Hum Toxicol 1:411–415 (1982).
23. Rabinowitz MB, Kopple JD, Wetherill GW. Effect of food
intake and fasting on gastrointestinal lead absorption in
humans. Am J Clin Nutr 33:1784–1788 (1980).
24. James H, Hilburn M, Blair J. Effects of meals and meal
times on uptake of lead from the gastrointestinal tract in
humans. Hum Toxicol 4:401–407 (1985).
25. Manton WI. Sources of lead in blood: Identification by
stable isotopes. Arch Environ Health 32:149–159 (1977).
26. Heaney RP. Calcium supplements: practical considera-
tions. Osteoporos Int 1:65–71 (1991).
27. Sowers MF, Corton G, Jannausch ML, Crutchfield M,
Smith ML, Randolph JF, Hollis B. Changes in bone den-
sity with lactation. JAMA 269:3130–3135 (1993). 
28. Sowers MF, Randolph J, Shapiro B, Jannausch M. A
prospective study of bone density and pregnancy after
an extended period of lactation with bone loss. Obstet
Gynecol 85:285–289 (1995).
29. Cross NA, Hillman LS, Allen SH, Krause GF. Changes in
bone mineral density and markers of bone remodelling dur-
ing lactation and postweaning in women consuming high
amounts of calcium. J Bone Miner Res 10:1312–1320 (1995).
30. Kalkwarf HJ, Specker BL. Bone mineral loss during lac-
tation and recovery after weaning. Obstet Gynecol
86:26–32 (1995).
31. Kalwarf HJ, Specker BL, Bianchi DC, Ranz J, Ho M. The
effect of calcium supplementation on bone density dur-
ing lactation and after weaning. N Engl J Med
337:523–528 (1997).
32. Krebs NF, Reidinger CJ, Robertson AD, Brenner M. Bone
mineral density changes during lactation, maternal,
dietary, and biochemical correlates. Am J Clin Nutr
65:1738–1746 (1997).
33. Rabinowitz MB, Wetherill GW, Kopple JD. Kinetic analy-
sis of lead metabolism in healthy humans. J Clin Invest
58:260–270 (1976).
34. Chamberlain AC, Heard MJ, Little P, Newton D, Wells
AC, Wiffen RD. Investigations into Lead from Motor
Vehicles. AERE-R9198. Harwell, UK:United Kingdom
Atomic Energy Authority, 1978.
35. Gulson BL, Davis JJ, Bawden-Smith J. Paint as a source
of recontamination of houses in urban environments and
its role in maintaining elevated blood leads in children.
Sci Total Environ 164:221–235 (1995).
36. Manton WI. Total contribution of airborne lead to blood
lead. Br J Ind Med 42:168–172 (1985).
37. Gulson BL, Mizon KJ, Palmer JM, Patison N, Law AJ,
Korsch MJ, Mahaffey KR, Donnelly JB. Longitudinal
study of daily intake and excretion of lead in newly-born
infants. Environ Res (in press). 
38. Stauber JL, Florence TM, Gulson BL, Dale LS.
Percutaneous absorption of inorganic lead compounds.
Science Total Environ 145:55–70 (1994). 
39. Manton WI, Angle CR, Stanek KL, Reese YR,
Kuehnemann TJ. Acquisition and retention of lead by
young children. Environ Res 82:60–80 (2000).
40. Gulson BL Mizon KJ, Palmer JM, Korsch MJ, Taylor AJ.
Unpublished data. 
41. Heaney RP. Availability of calcium from various sources.
Bone 7:54–56 (1990).
42. Ziegler EE, Edwards BB, Jensen RL, Mahaffey KR, Fomon
SI. Absorption and retention of lead by infants. Pediatr
Res 12:29–34 (1978).
43. Mahaffey KR, Treloar S, Banks TA, Peacock BJ, Parekh
LE. Difference in dietary intake of calcium phosphorus
and iron of children having normal and elevated blood
lead concentrations [Abstract ]. J Nutr 106:7 (1976). 
44. Sorrell M, Rosen JF, Roginsky MR. Interactions of lead,
calcium, vitamin D and nutrition in lead-burdened chil-
dren. Arch Environ Health 32:160–164 (1977).
45. Johnson NE, Tenuta K. Diets and blood leads of children
who practice pica. Environ Res 18:369–376 (1979).
46. Mahaffey-Six KR, Goyer RA. Experimental enhancement
of lead toxicity by low dietary calcium. J Lab Clin Med
76:933–941 (1970).
47. Mahaffey KR, Haseman JD, Goyer RA. Dose-response to
lead ingested in rats fed low dietary calcium. J Lab Clin
Med 83:92–100 (1973). 
48. Quarterman J, Morrison NJ, Humphries WR. The influ-
ence of high dietary calcium and phosphate on lead
uptake and release. Environ Res 17:60–67 (1978).
49. Meredith PA, Moore MR, Goldberg A. The effect of calcium
on lead absorption in rats. Biochem J 16:531–537 (1977).
50. Barltrop D, Khoo HE. The inﬂuence of nutritional factors
on lead absorption. Postgrad Med J 51:795–799 (1975)
51. Ragan HA. Effect of iron deficiency on the absorption
and distribution of lead and cadmium in rats. J Lab Clin
Med 90:700–706 (1977).
52. Fine B, Barth A, Sheffet A, Levenhar MA. Influence of
magnesium on the intestinal absorption of lead. Environ
Res 12:224–227 (1976).
53. Natural Resources Defense Council News Release.
NRDC reaches legal settlement with largest calcium
supplement manufacturer to provide “lead-free” cal-
cium. New York:Natural Resources Defense Council, 27
January 1997. 
54. Lanphear BP, Dietrich KN, Auinger P, Cox C. Subclinical
lead toxicity in U.S. children and adolescents [Abstract].
Pediatr Res 47:894 (Part 2, suppl) (2000). 
Articles • Gulson et al.
288 VOLUME 109 | NUMBER 3 | March 2001 • Environmental Health Perspectives
•  Environmental Health Perspectives •  Environmental Health Perspectives Supplements
•  National Toxicology Program Technical and Toxicity Reports  •  Report on Carcinogens
•  Chemical Health and Safety Database  •  Rodent Historical Control Database
Visit us online!
Environmental Health
  Information Service
Environmental Health Information Service